Fierce Healthcare

Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Ly

Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase ...
Monthly Prescribing Reference

Phase 2 study of blinatumomab (MT103) for the treatment of acute lymphoblastic leukemia (ALL)

Micromet announced updated results from a Phase 2 trial of blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). This multi-center ...
Medindia

Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas

BETHESDA, Md., May 22 Micromet, Inc.(Nasdaq: MITI), a biopharmaceutical company developing novel, proprietaryantibodies for the treatment of cancer, inflammation and autoimmune diseases,today ...
FierceBiotech

Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Ly

Several antibodies in Micromet's product pipeline are BiTE antibodies and have been generated based on Micromet's proprietary BiTE antibody platform. The most advanced BiTE antibody is MT103 (MEDI-538 ...
Medindia

Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma

BETHESDA, Md., June 5 Micromet, Inc.(Nasdaq: MITI), a biopharmaceutical company developing novel, proprietaryantibodies for the treatment of cancer, inflammation and autoimmune diseases,today ...